Enter your search terms:

MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery

PharmFilm® shown effective in buccal delivery of Octreotide and Exenatide

Warren, N.J., October 13, 2015 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, recently presented on the Company’s advancements in oral peptide drug delivery utilizing its PharmFilm technology at The Boulder Peptide Symposium, Boulder, CO, and Partnerships in Drug Delivery Conference 2015, Boston, MA,. Nozer Mehta Ph.D., MonoSol Rx Vice President of Biologics, was the presenter at both conferences.

The oral podium presentations, entitled “Advantages of Mucoadhesive Buccal Films for the Delivery of Peptides” and “Advantages of PharmFilm® Buccal Delivery Technology for Small Molecules and Peptides” highlighted the company’s study of buccal peptide delivery with Exenatide and Octreotide. These chronic therapy drugs, like the majority of peptides, are traditionally delivered by injection.

Dr. Mehta commented, “MonoSol Rx’s PharmFilm technology already boasts a number of technical advantages as a drug delivery technology. As we actively expand our development pathway to include peptide drugs to our pipeline, the findings from the early preclinical studies support the successful application of this technology for oral peptide delivery.”

Keith Kendall, CEO of MonoSol Rx, also added “We are extremely encouraged by the progress MonoSol Rx has made on the small molecule and peptide delivery fronts. By providing patients a non-injectable alternative to everyday drugs using PharmFilm technology, we can develop more valuable and innovative products for patients and caregivers.  Through this work we further demonstrate that MonoSol Rx is a specialty pharmaceutical company at the forefront of research, development, and innovation.”

MonoSol Rx currently has two commercialized oral film products: Suboxone® (Buprenorphine/Naloxone) for the treatment of opioid dependence and Zuplenz® (Ondansetron) for treatment of nausea and vomiting in patients receiving chemotherapy. The Company also has additional complex molecule product candidates currently in various stages of preclinical development.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients.  PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs.  The Company’s leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals — Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence.  For press releases and other company information visit www.monosolrx.com.

About Exenatide

Exenatide is currently marketed as BYETTA, an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise.

About Octreotide

Octreotide, the active ingredient in Sandostatin® injection and Sandostatin® LAR Depot (octreotide acetate for injectable suspension), has been studied for over 20 years, and is approved for the treatment of acromegaly and carcinoid syndrome.

Latest comments

Sorry, the comment form is closed at this time.